Oncolytic virotherapy is a promising avenue of cancer gene therapy. Current vectors include human viruses that have been engineered to replicate in tumor cells or nonhuman viruses that are naturally oncotropic and preferentially replicate in tumor cells harboring defects in innate immune pathways such as the type 1 interferon (IFN) pathway. Bovine herpesvirus type 1 (BHV-1) is a species-specific herpesvirus closely related to the human herpes simplex virus type 1 (HSV-1). Although BHV-1 does not efficiently replicate in and affect cellular viability of normal human cells, it is capable of infecting and killing various immortalized and transformed human cell types. Surprisingly, BHV-1 infection of human cells fails to elicit IFN production at the mRNA or protein level and the ability of BHV-1 to kill immortalized and transformed human cells does not correlate with defects in IFN pathways. Furthermore, although some cross-reactivity between BHV-1 and HSV-1 exists, the majority of human antibody or serum samples tested failed to neutralize BHV-1 despite possessing HSV-1 neutralizing capacity. Thus, BHV-1 is a novel candidate oncolytic virus with a distinct mechanism of tumor targeting.
Introduction
Oncolytic virotherapy is based on the observation that some viruses propagate in and kill cancer cells while displaying minimal adverse effects in normal healthy cells. 1, 2 Two main forms of oncolytic viruses exist: naturally occurring wild-type oncolytic viruses and modified viruses engineered to achieve selective oncolysis. The collection of gain-of-function or loss-of-function mutations characteristic of a given malignant cancer type will determine the nature of the selective growth advantage over normal cells for an oncolytic virus. 1 For example, many cancer cells are resistant to apoptosis due to gain-of-function mutations in cellular signaling proteins such as Ras. Activated Ras leads to the inhibition of the double-stranded RNA-dependent protein kinase R (PKR), an important factor in the interferon (IFN)-mediated antiviral response. Accordingly, wild-type viruses that are normally sensitive to the effects of PKR, such as reovirus, along with viruses deleted in proteins that function to block PKR, such as ICP34.5-null mutants of herpes simplex virus type 1 (HSV-1), preferentially replicate in cancer cells harboring activated Ras. Another gain-of-function mutation in cancer cells that oncolytic viruses exploit is the increased expression of cell surface receptors. For many oncolytic viruses, however, selectivity for cancer cells is based on loss-of-function mutations in key antiviral response systems, such as the IFN system.
IFN is a family of innate cytokines that possesses antiviral, antiproliferative and immunoregulatory properties. 3 Although IFN per se does not harbor these pleiotropic properties, it initiates the induction of various IFN-stimulated genes (ISGs) following binding to cellular IFN receptors. Of no surprise, diminished IFN responsiveness is a common genetic dysfunction during tumor evolution. 4, 5 Accordingly, wild-type viruses or engineered virus mutants whose replication is inhibited by IFN, preferentially replicate in these cells but not normal cells. Examples include vesicular stomatitis virus (VSV), Newcastle disease virus (NDV), myxoma virus and ICP0-null HSV-1 oncolytic vectors. [6] [7] [8] [9] HSV-1 vectors have generated much interest in the field, as HSV-1 was the first virus used to show that a genetic mutation could render a virus oncolytic. To date, Phase I and II clinical trials have been conducted with various HSV-1 mutants, showing the safety of administering various oncolytic mutants of HSV-1 in humans. [10] [11] [12] [13] Although HSV-1 oncolytic vectors possess many properties that make this virus well suited for oncolytic virotherapy, there are a number of disadvantages with this platform. As a human pathogen, HSV-1 must be genetically manipulated to attenuate the virus sufficiently for it to preferentially replicate in tumor cells. Attenuation makes large-scale production less efficient, as genetically modified viruses generally do not generate as high titers of progeny virus as wild-type viruses. Furthermore, it has been estimated that 40-90% of the population has preexisting immunity to HSV-1, 14, 15 which precludes efficient systemic delivery of HSV-1 oncolytic vectors.
Consequently, the use of wild-type viruses that are not human pathogens is being developed as an alternative approach for oncolytic virotherapy. 16 Given the advantages of herpesvirus vectors such as HSV-1, we investigated the potential of bovine herpesvirus type 1 (BHV-1) as an oncolytic vector. BHV-1 is a widespread cattle pathogen that, similar to HSV-1, is a member of the alphaherpesvirus subfamily. Acute BHV-1 infection causes lesions on mucosal surfaces, followed by the establishment of life-long latency in neurons. 17 BHV-1 induces bovine respiratory disease, also known as 'shipping fever,' through transient immunosuppression. 17 This phenomenon is mostly associated with reactivation of the virus from latency following a stress response. In the absence of bacterial pneumonia seen in shipping fever, BHV-1 symptoms are typically cleared within 2-6 days. The structure and life cycle of BHV-1 are similar to HSV-1, including the recognition of the attachment and entry receptors heparin sulfate and nectin-1. 18 However, unlike HSV-1, BHV-1 is unable to bind to host nectin-2, but is capable of recognizing the poliovirus receptor CD155, 18 a receptor associated with tumor cell migration and invasion. 19 One of the interesting features of BHV-1 is its strict host range compared with other herpesviruses, including HSV-1. Of particular interest is the inability of BHV-1 to productively infect human cells, 20 supported by the lack of reports of either productive BHV-1 infection or even BHV-1 as a novel oncolytic virus R Rodrigues et al seroconversion in humans, 21 suggesting that there is a block to BHV-1 infection in human cells that is downstream of cellular entry. Similarly, wild-type mice infected with BHV-1 show no clinical symptoms, whereas mice lacking type I and type II IFN receptors in the context of a RAG-2 gene deletion die a few days following infection. 22 This observation suggests that IFN signaling may contribute to the host range of BHV-1. Of interest, an early report from the 1960s showed that infectious bovine rhinotracheitis virus, now recognized as BHV-1, is cytopathic in various transformed human cell lines in vitro, including HeLa, KB, HEp-2 and Had-1 cell lines. 21 In this study, we determined the ability of BHV-1 to replicate, cause cytopathic effects and affect cellular viability in a panel of normal, immortalized and transformed human cells from a variety of histological origins. We found that BHV-1 replicates and induces cytopathic effects in a wide subset of immortalized and transformed cells, thus decreasing cellular viability, but is significantly restricted in normal cells. Furthermore, cellular permissiveness to BHV-1-mediated oncolysis failed to correlate with IFN signaling status, suggesting that alternative genetic lesions in immortalized and transformed cells modify the restriction to BHV-1 infection in human cells.
Materials and methods

Cell lines
Information on all human cell lines used in this study is found in Table 1 . All cell types were maintained at 37 1C þ 5% CO 2 in media supplemented with 2 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin and were purchased from the American Type Culture Collection (Manassas, VA) unless noted otherwise. MDA-MB-231, MDA-MB-468, BJ and MRC-5 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). U2OS, HEL and Vero (African green monkey kidney) cells were maintained in DMEM with 8% FBS. CCD-1140Sk fibroblasts were maintained in DMEM with 12% FBS. Madin-Darby bovine kidney (MDBK) cells were a kind gift from Dr Vikram Misra (University of Saskatchewan) and were grown in DMEM with 10% horse serum. FOB cells were grown in DMEM supplemented with 10% FBS and 500 mg ml À1 of G418 (Sigma, St Louis, MO) at 34.9 1C. PC-3, PC-3M, PC-3M-M2, PC-3M-Pro4 and PC-3M-LN4, kindly provided by Dr Isaiah Fidler (University of Texas), were maintained in RPMI medium supplemented with 10% FBS and 5 mM sodium pyruvate. RWPE-1 cells were grown in serum-free keratinocyte medium (Gibco, Carlsbad, CA) supplemented with 25 mg ml À1 bovine pituitary extract (BPE) and 5 ng ml À1 human epidermal growth factor. Patient matched benign and malignant prostate epithelial cells (1532-NPTX and 1532-CP2TX, 1535-NPTX and 1535-CP1TX, and 1542-NPTX and 1542-CP3TX) were maintained in the above medium, supplemented with 5% FBS. A549 cells were grown in a-minimum essential medium (a-MEM) with 10% FBS. MCF-10A and HME-1 cells were maintained in mammary epithelial growth medium (MEGM) with 10% FBS and 13 mg ml À1 BPE. Primary human adult lung fibroblasts (Ventressca and Ronald cell lines) were a kind gift from Dr Jack Gauldie (McMaster University) and maintained in MEM/F15 with 15% FBS.
Viruses HSV-1 strain KOS was propagated and titrated on Vero cells, whereas the HSV-1 oncolytic vector KM100 9 was propagated and titrated on U2OS cells. BHV-1 strain Cooper and BHV-1 expressing green fluorescent protein Figure 2 Permissiveness of immortalized and transformed cells to bovine herpesvirus type 1 (BHV-1). Cells were infected with the indicated MOI of BHV-1. Three days post-infection, cell monolayers were stained with Giemsa to observe and score cytopathic effect (CPE): þ þ þ indicates very permissive cells, in which 50% CPE was seen at an MOI o1; þ þ indicates a moderately permissive cell type, in which 50% CPE was seen between MOIs of 1 and 2.5; þ indicates a cell type that is not very permissive, showing 50% CPE at an MOI 42.5; À indicates a non-permissive cell type in which no CPE is observed at MOIs between 0.5 and 10. MOI, multiplicity of infection. 4 were provided by Dr Brian Lichty (McMaster University). All virus stocks were sucrose cushion purified.
Cytopathic effect assays
For all cytopathic effect (CPE) assays, 90-95% confluent cell monolayers were infected with virus at the indicated multiplicity of infection (MOI) in serum-free medium. Following viral adsorption for 1 h at 37 1C, cells were maintained in medium with 5% FBS. Infection of RWPE-1 cells was done with serum-free keratinocyte medium and cells were maintained in the appropriate growth medium. Three days post-infection, cells were fixed with methanol and stained with Giemsa to visualize CPE. Observed CPE was scored based on the MOI of virus required to induce CPE in 50% of the cell monolayer and was assessed blinded.
Virus replication and cell viability assays
For all virus replication assays, 90-95% confluent cell monolayers were infected with BHV-1gfp at the indicated MOI in serum-free medium. After viral adsorption for 1 h at 37 1C, cells were maintained in medium with 1% FBS. GFP fluorescence from BHV-1gfp replication was quantified at 1 and 2 days post-infection using a Typhoon BioAnalyzer (Amersham Biosciences, Uppsala, Sweden). Viral replication was represented by absolute fluorescence units (FU). Two days post-infection, cell viability was assessed. Specifically, Alamar blue (5% (v/v); Biosource, Carlsbad, CA) and 5-carboxyfluorescein diacetate-acetoxymethylester (CFDA-AM) (4 mM; Invitrogen, Carlsbad, CA) were diluted in phosphate-buffered saline (PBS) and added to cells followed by incubation for 30 min at 37 1C. Fluorescence was read using a Safire fluorescence plate reader (Tecan, Mannedorf, Switzerland) and fold change in fluorescence from untreated controls was calculated. Data are expressed as means from three independent experiments ± s.e.m.
IFN responsiveness assays
Subconfluent monolayers of cells were treated with 1000, 100, 10, 1 and 0.1 U ml À1 of human IFNa (Sigma) in medium with 5% FBS, for 24 h at 37 1C, after which the cells were infected with VSV-GFP for 1 h at 37 1C. Medium with 2% methylcellulose and 5% FBS was added to the cells following viral adsorption to promote plaque formation. The quantity of VSV-GFP used for infections varied for each cell line and was determined by titration of VSV-GFP on each cell line in the absence of IFN to determine the dilution of VSV-GFP yielding fluorescence in a linear range for quantification. GFP fluorescence from VSV-GFP replication was quantified 24 h post-infection using a Typhoon BioAnalyzer (Amersham Biosciences). Mean GFP fluorescence for each treatment was normalized to an uninfected, untreated control for each cell line. Relative fluorescent units of normalized samples were calculated as a percentage of IFN untreated, infected controls. The effective concentration of IFN required to reduce GFP fluorescence by 50% (EC 50 ) was calculated.
IFN production assay Cells were infected with VSVDM51, KM100 and BHV-1gfp at MOIs of 0.5 and 5. Supernatants were collected at 24 h post-infection and virus in the supernatant was ultraviolet (UV)-inactivated at 9999 kJ with a UV Stratalinker 2400 BHV-1 as a novel oncolytic virus R Rodrigues et al (Stratagene, La Jolla, CA). Virus inactivation was confirmed by a failure to detect GFP fluorescence and CPE on control monolayers (data not shown). Naive Vero cells were treated with UV-inactivated supernatants for 24 h, followed by a standard IFN responsiveness assay.
Western blot analysis
Protein was harvested from mock treated and infected cells at 24 and 36 h post-infection. Cells were collected by centrifugation at 200 Â g for 3 min at 4 1C. Pellets were washed with 10 ml of cold PBS and resuspended in whole cell extract buffer (20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.4, 100 mM NaCl, 10 mM b-glycerophosphate, 0.2% Triton X-100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM dithiothreitol (DTT), 1 Â protease inhibitor cocktail (Sigma)) and lysed on ice for 15 min. Lysates were centrifuged at 13 000 Â g for 10 min at 4 1C and the supernatants were collected. Protein was quantified using the Bradford Figure 4 Quantification of cellular viability after BHV-1gfp infection in normal, immortalized and transformed cells. Two days post-infection of BHV-1gfp with the indicated MOI, cell metabolism and membrane integrity were assessed, as measured by Alamar blue and CFDA-AM fluorescence, respectively. Fluorescence was read using a Safire fluorescence plate reader and fold change in fluorescence from untreated controls was calculated. Data are expressed as means from three independent experiments ± s.e.m. MOI, multiplicity of infection.
BHV-1 as a novel oncolytic virus
R Rodrigues et al assay kit (Bio-Rad Laboratories, Hercules, CA). Whole cell extracts were boiled in sample buffer containing sodium dodecyl sulfate (SDS) and b-mercaptoethanol, run on a 7.5% polyacrylamide gel and were transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA) with a semi-dry transfer apparatus at 400 mA for 1 h. All blots were blocked in 5% skim milk in Trisbuffered saline (TBS) at room temperature for 1 h. Blots were probed with a pan-specific rabbit HSV-1 primary antibody (Dako, Glostrup, Denmark), diluted at 1:1000 in TBS-Tween (0.1%), for 1 h at room temperature, followed by an anti-rabbit secondary antibody conjugated to horseradish peroxidase (HRP) (Sigma) diluted at 1:5000 in 5% skim milk in 0.1% TBS-Tween. Blots were visualized by chemiluminescence. Solution A (100 mM Tris, pH 8, 90 mM p-coumaric acid (Sigma), 250 mM luminol (Sigma)) was mixed with solution B (100 mM Tris, pH 8, 0.06% H 2 O 2 ) and added to the blot for 30 s, after which blots were exposed to film.
Virus neutralization assays
A pan-specific polyclonal rabbit HSV-1 primary antibody (Dako), pooled human serum (Sigma) or individual donor serum was diluted two-fold in serum-free medium. Serum derived from healthy donors was obtained with the approval of the McMaster University Research Ethics Board. Diluted serum was incubated with 100 plaque forming units (pfu) of BHV-1 or KOS, for 1 h at 37 1C. Confluent monolayers of U2OS cells in a 12-well plate were infected for 1 h. After viral adsorption, 2% methylcellulose with 5% FBS was added to allow for plaque formation. Cells were fixed with methanol and stained with Giemsa 2-3 days post-infection, and plaques were counted.
RT-PCR
RNA was isolated from mock, VSVDM51, KM100 and BHV-1gfp infected samples at 6 h post-infection using Trizol reagent (Invitrogen) according to the manufacturer's instructions. RNA was reverse-transcribed using 0.1-1 mg of RNA, 200 ng of random 6-mer primer and 100 U of SuperScript II Reverse Transcriptase (Invitrogen). PCR was carried out using 2 ml of cDNA and Taq 
Results
BHV-1 replication is restricted in normal human cells
Unlike many herpesviruses, BHV-1 has a restricted host range and is unable to productively infect humans, despite its similarities with HSV-1. 20 Myxoma virus, a rabbit poxvirus with a similar restricted tropism, functions as an oncolytic virus in human tumor cells bearing deficiencies in type I IFN and tumor necrosis factor-a (TNFa) pathways. 23, 24 Before investigating the oncolytic capacity of BHV-1, we first confirmed the restriction of normal human cells against BHV-1 replication and CPE induction. A panel of six non-immortalized, non-transformed cell types (refer to Table 1 for cell type information) were infected with increasing amounts of BHV-1, and CPE was monitored 3 days post-infection. As shown in Figure 1 , three cell lines (HEL, Ronald and CCD-1140Sk) were refractory to BHV-1-mediated CPE induction, whereas three different cell lines (Ventressca, MRC-5 and BJ) showed CPE after high multiplicity infection with BHV-1. Although it is possible that HEL, Ronald and CCD1140Sk fail to show CPE after BHV-1 infection due to the inability of BHV-1 to enter into these cell lines, this possibility is unlikely given that BHV-1 recognizes the same attachment and entry receptors on human cells as HSV-1, 18 and all of the cell lines used in this study are susceptible and permissive to infection by wild-type HSV-1 (data not shown).
BHV-1 demonstrates lytic capacity in various immortalized and transformed human cell types
To assess the oncolytic capacity of BHV-1, a panel of immortalized and transformed human cells from multiple histological origins was subjected to BHV-1 infection. As the ability to cause damage sufficient to kill susceptible cells is not directly linked to subsequent infectious virus production, CPE was assessed as opposed to viral titers. To compare the relative permissiveness of each cell line, the observed CPE was scored based on the MOI of BHV-1 as a novel oncolytic virusvirus required to induce CPE in B50% of cells, with representative images of CPE and the corresponding scores outlined in Figure 2 . BHV-1 was capable of inducing CPE in transformed cells from lung, mammary, bone and prostate origins, with varying efficiency (Table 2) . Of particular interest, BHV-1 also induced CPE in immortalized cells of various histological origins, suggesting that alteration of cell cycle status affects the cellular permissiveness for BHV-1 oncolysis.
To quantify these observations and characterize the relationship between virus replication, cellular viability and observable CPE, we analyzed a subset of these cell types (four normal, three immortalized and six transformed) for virus replication using BHV-1gfp, and cellular viability using Alamar blue and CFDA-AM to measure cell metabolism and membrane integrity respectively. Virus replication, quantified as absolute FU based on GFP fluorescence under control of a viral immediate early promoter, was relatively restricted in normal cells compared with immortalized and transformed cells (Figure 3) . Consistent with CPE results outlined in Table 2 , immortalized FOB cells showed a higher level of virus replication relative to 1532-NPTX and 1542-NPTX (middle panel). Also consistent with CPE results, A549 and U2OS cells showed the highest level of virus replication. While the lack of GFP fluorescence for 1532-CP2TX would suggest that these cells fail to support significant virus replication, as predicted by CPE analysis, we noted that within 24 h of infection, cells had lifted from the plate and appeared dead (data not shown), which is consistent with an abrupt decrease in cellular viability (Figure 4) . The only discrepancy between CPE analysis and virus replication was observed with the transformed mammary cell lines MDA-MB-231 and MDA-MB-468, which appeared to support similar levels of virus replication despite differences in CPE.
When two aspects of cellular viability were quantified, we observed that infection of normal cells with BHV-1gfp failed to significantly alter either cell metabolism or membrane integrity, whereas infection of immortalized and transformed cells with BHV-1gfp resulted in decreased cellular viability (Figure 4) . The relative decrease in cellular viability in immortalized and transformed cells correlated well with both CPE and virus replication analyses. Of interest, we observed a more dramatic drop in cellular viability in MDA-MB-468 cells relative to MDA-MB-231 cells, consistent with CPE analysis.
Cellular permissivity to BHV-1 does not correlate with responsiveness to type I IFN It has been shown for various oncolytic viruses, including VSV, NDV, myxoma virus and ICP0-null HSV-1 oncolytic vectors, that permissiveness of cancer cells correlates with impaired type I IFN signaling. [6] [7] [8] [9] Thus, a subset BHV-1 as a novel oncolytic virus R Rodrigues et al of the panel of cell types screened for susceptibility to BHV-1-mediated CPE was assayed for IFN responsiveness to determine whether IFN signaling influences permissiveness to BHV-1 infection. Cells were treated with human IFNa for 24 h before infection with VSV-GFP. VSV replication, as estimated by GFP fluorescence, was used to assess the IFN responsiveness of each cell line, as cells responsive to IFN will be unable to support VSV replication. The EC 50 of IFN was calculated to compare IFN responsiveness between cell lines (Table 3 ). The normal and immortalized cells used in this study were all responsive to IFN treatment, with EC 50 values ranging from 0.5 U ml À1 (MCF-10A) to 1.5 U ml À1 (HEL). However, the transformed cells were overall less responsive to IFN treatment, with EC 50 values ranging from 1.3 U ml À1 (MDA-MB-231) to 41.2 U ml À1 (U2OS). Importantly, the susceptibility to BHV- , respectively), yet FOB cells were highly susceptible to BHV-1-mediated oncolysis, whereas little-to-no CPE was observed in HEL cells, even after high multiplicity infection (Figure 1) . Thus, unlike the related ICP0-null HSV-1 vectors and the species-specific nonhuman oncolytic viruses, BHV-1-mediated oncolysis does not correlate with responsiveness to type I IFN.
BHV-1 infection does not elicit type I IFN production
Naturally oncotropic viruses such as VSV, NDV and myxoma virus elicit type I IFN production in normal human cells, thus restricting their replication and induction of CPE. As the oncolytic capacity of BHV-1 does not correlate with type I IFN status, we asked whether BHV-1 infection of human cells resulted in IFN production. Normal fibroblasts (MRC-5 and CCD-1140Sk), immortalized bone osteoblasts (FOB) and adult lung carcinoma cells (A549) bearing intact IFN production pathways were infected with BHV-1, the HSV-1 oncolytic vector KM100 and the VSV oncolytic vector VSVDM51. In contrast to VSVDM51, BHV-1 failed to produce IFNb mRNA above background levels in these cells and KM100 induction of IFNb mRNA was observed only in normal fibroblasts (Figure 5a ). We failed to detect IFNb mRNA in FOB cells regardless of the virus used, despite detection of IFNb activity within supernatants from VSVDM51-infected cells. Supernatants harvested from all cells infected by VSVDM51 showed antiviral activity, whereas supernatants from KM100-or BHV-1-infected cells failed to protect naive monolayers from subsequent virus infection (Figure 5b ).
Neutralization activity against HSV-1 is not predictive of cross-reactive activity against BHV-1 One of the potential advantages of using BHV-1 as an oncolytic vector over HSV-1 is the possibility of circumventing preexisting immunity, which would allow for more effective systemic delivery in HSV-1 seropositive cancer patients. Previously, it has been reported that rabbit polyclonal antibodies against HSV-1 and BHV-1 gB cross-react. 25 We investigated the ability of a rabbit polyclonal pan-HSV-1 antibody to bind to BHV-1 proteins. U2OS cells were infected with either BHV-1 or HSV-1, and whole cell extracts were harvested at 24 and 36 h post-infection for western blot analysis. Although a spectrum of HSV-1 proteins were detected at 24 and 36 h post-infection, BHV-1 proteins were not recognized by this antibody at the time points examined (Figure 6a ), despite robust CPE and virus replication in these cells (Figures 2 and 3) . Consistent with this observation, this polyclonal antibody was able to neutralize HSV-1 but not BHV-1 (Figure 6b ). Next, we BHV-1 as a novel oncolytic virus R Rodrigues et al Figure 7 Herpes simplex virus type-1 (HSV-1) neutralizing activity in human serum is not predictive of cross-reactive bovine herpesvirus type 1 (BHV-1) neutralizing activity. Two-fold dilutions of pooled human serum (Sigma) (a) or individual healthy donor samples (b) were incubated with 100 pfu of virus for 1 h before infection of U2OS cells. Cells were stained at 3 days post-infection and plaques were counted. Data are expressed as means from three independent experiments ± s.e.m. pfu, plaque forming unit.
BHV-1 as a novel oncolytic virus
R Rodrigues et al investigated the ability of components of human serum to neutralize BHV-1. Both HSV-1 and BHV-1 were incubated with two-fold dilutions of pooled human serum (Sigma; Figure 7a ) or serum derived from six healthy donors (Figure 7b ) before infection of U2OS cells. Pooled human serum neutralized HSV-1, but failed to neutralize BHV-1. In three of six donors (1, 3 and 4), we detected neutralization against both HSV-1 and BHV-1 at relatively high serum concentrations. In the other three donors (2, 5 and 6), we detected more robust neutralization of HSV-1, but not BHV-1. Overall, we failed to detect significant neutralization of BHV-1 under the majority of conditions tested, suggesting that although HSV-1 antibodies likely cross-react with BHV-1 proteins, this activity is not observed in all people.
Discussion
Oncolytic viruses offer many potential advantages over conventional cancer treatments, including the lack of adverse side effects and the ability of oncolytic viruses to also function as tumor vaccines. 1, 2, 26 Nonhuman wildtype oncolytic viruses display several advantages over engineered human vectors, including limited or absent infection in humans, the absence of preexisting immunity, the lack of engineering required to attenuate the virus and the likelihood of growth to higher titers than attenuated mutants for production purposes. BHV-1 has no pathogenic profile in humans, yet productively replicates and kills a variety of human cancer types. Although several other bovine viruses are being developed as oncolytic viruses, including bluetongue virus 10 (a segmented, dsRNA virus of the family Reoviridae), 27 bovine enterovirus (a ssRNA virus of the family Picornaviridae) [28] [29] [30] and bovine herpesvirus 4 (a gammaherpesvirus of the genus Rhadinovirus), 31 BHV-1 offers several advantages. First, although bluetongue virus 10, bovine enterovirus and bovine herpesvirus 4 replicate in a broad range of mammalian cells, BHV-1 replication is normally restricted to bovine cells. Second, BHV-1 infection can be controlled by bromovinyldeoxyuridine (BVDU), also known as brivudine, at low concentrations. 32 This drug is currently used in the clinic in many European countries to control herpes zoster infections. Third, BHV-1 is easily grown and manipulated, facilitating the addition of therapeutic transgenes if warranted. In addition, a vaccine for BHV-1 has been developed, 33 which will facilitate regulatory approval of such agriculturally important virus species pending successful clinical trials.
As our appreciation of the complexity of genetic lesions underlying tumorigenesis increases, so does the reality that no single therapeutic modality will suffice to eliminate all forms of cancer. This reality has been observed with oncolytic viruses, in that all oncolytic viruses characterized to date show efficacy in tumor killing in only a subset of human tumors. Thus, elucidating the genetic parameters that influence cellular permissivity along with understanding the mechanisms of virus-mediated tumor cell killing is of utmost importance to successfully develop the therapeutic potential of a particular oncolytic virus. Given the observation that myxoma virus, a rabbit virus with a strict species tropism, was able to overcome species-specific barriers to replication in cells harboring defects in IFN and TNFa pathways, 7, 23 along with the observation that several other nonhuman viruses (for example, VSV and NDV) also preferentially replicate in such cells, we hypothesized that BHV-1 similarly replicates in cells deficient for IFN signaling. However, we failed to detect a correlation between cellular IFN signaling status and permissiveness for BHV-1. Furthermore, we observed that BHV-1 infection of normal, immortalized or transformed cells capable of IFN production failed to elicit type I IFN production, at either the mRNA or protein level. Conversely, the prototypic VSV oncolytic virus, VSVDM51, induced active IFN in all cell types. We did not observe significant IFN activity in supernatants of cells infected with the HSV-1 ICP0-null oncolytic vector KM100, despite being able to detect IFNb mRNA in infected fibroblasts. Not surprisingly, however, human cells responsive to IFN were able to limit BHV-1 replication upon pretreatment with exogenous IFN (data not shown).
Of particular interest, BHV-1 was capable of inducing CPE in non-transformed cells that had been immortalized by various approaches, including the expression of hTERT, SV40 large T antigen or the HPV proteins E6 and/or E7. CPE results were confirmed by quantification of virus replication and cellular viability. Often, immortalized cells are referred to in the literature as 'phenotypically normal,' as they are not transformed. The ability of BHV-1 to induce significant CPE in a number of immortalized cell lines raises the question of how many cellular changes are required to render a cell susceptible to cancer therapy. Immortalization of primary cells is often accomplished through expression of viral proteins that control cell cycle progression, such as p53 and pRB, whose loss of function has a key role in the development of many human cancers. Thus, BHV-1 may be particularly sensitive to the cell cycle status of human cells and may target cells that have incurred defects in cell cycle regulation. Current studies are underway to address the mechanism of BHV-1-mediated lysis of immortalized and transformed human cells.
Overall, these studies suggest that BHV-1 is a novel oncolytic virus with a mechanism of action distinct from other species-specific viruses. Given the heterogeneity of defects that lead to tumor formation, the development of novel oncolytic vectors with distinct modes of action will expand the arsenal of vectors used to target cancer cells.
